ATB-238
/ AUTOTAC Bio
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 18, 2026
Characterization of second-generation AUTOTACs targeting the androgen receptor for castrate-resistant prostate cancer treatment
(AACR 2026)
- "We previously reported the characterization of ATC-324, the first-generation AR-targeting AUTOTAC utilizing enzalutamide (ENZ) as a target-binding ligand (TBL) and YT 6-2 as an autophagy targeting ligand (ATL)...ATB-238 and ATB-239 exhibited high potency against 22Rv1 micrometastases in BICA, while ATB-238 synergizes with docetaxel in killing LNCaP and CWR-R1 cells. ATB-238 and ATB-239 represent significant advances in AR-targeted therapeutics, capable of degrading AR variants and overcoming therapy resistance. ATB-238 and ATB-239 represent significant advances in AR-targeted therapeutics, capable of degrading AR variants and overcoming therapy resistance. The ongoing intra-iliac-artery xenograft studies will assess their potential to inhibit PCa bone metastasis, an incurable stage of the disease. These findings highlight the therapeutic promise of AUTOTAC technology in addressing critical challenges in CRPC treatment."
Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR
March 26, 2025
Characterization of second-generation AUTOTACs targeting the androgen receptor for castrate-resistant prostate cancer treatment [WITHDRAWN]
(AACR 2025)
- "We previously reported the characterization of ATC-324, the first-generation AR-targeting AUTOTAC utilizing enzalutamide (ENZ) as a target-binding ligand (TBL) and YT 6-2 as an autophagy targeting ligand (ATL)...Importantly, ATB-238 and ATB-239 can serve as sensitizers to radio- and chemotherapy such as docetaxel... ATB-238 and ATB-239 represent significant advances in AR-targeted therapeutics, capable of degrading AR variants and overcoming therapy resistance. Both compounds exhibit superior AR degradation efficiency compared to the first-generation ATC-324. The ongoing intra-iliac-artery xenograft studies will assess their potential to inhibit prostate cancer bone metastasis, an incurable stage of the disease."
Castration-Resistant Prostate Cancer • Castration-Sensitive Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR
1 to 2
Of
2
Go to page
1